Bank of America raised its peak sales forecast for Johnson & Johnson's oral psoriasis drug Icotyde to $4.5 billion, up from $2.4 billion, reflecting increased market share assumptions and a sector rerating favoring defensive stocks. The broker projects $70 million in sales for Q3 2026 and $220 million for the full year, aligning with consensus estimates. Despite limited prescription data, the firm maintained overall 2026 revenue forecasts at $25.5 billion with 6% growth, factoring in recent acquisitions and collaborations that increase R&D expenses. Investors should watch upcoming earnings for updates on Icotyde's launch and other product developments.
Johnson & Johnson shares are trading at USD 267.12 on Pluang as of September 30, 2026, 02:21 WIB, down 1.77% for the day. The stock's market cap stands at $655.37 billion, reflecting its significant presence in the health sector. Despite the recent downgrade in price, investors show a high sell activity of 94% on Pluang, indicating cautious sentiment around the stock amid its evolving product pipeline.
Johnson & Johnson will announce its third-quarter results on October 13. The company saw a 6.6% revenue increase in Q2 to $25.31 billion, driven by strong sales in its multiple myeloma portfolio and the drug Tremfya. Recent data suggests a significan...
Johnson & Johnson announced new two-year data from a Phase 2/3 study showing that IMAAVY (nipocalimab) provides sustained disease control, improved muscle strength, and reduced corticosteroid use in adolescents with generalized myasthenia gravis (gMG...
Johnson & Johnson is poised for growth with a strong oncology and immunology pipeline, including promising drugs like CARVYKTI and TREMFYA showing significant progress. The company reported a 56% stock rally over the past year and raised earnings gui...
Procter & Gamble, Johnson & Johnson, and Coca-Cola have each increased their dividends annually through eight major economic downturns since the 1960s, including stagflation, recessions, and the pandemic. These companies have strong cash flows and so...
AbbVie and Johnson & Johnson are both strong dividend stocks trading near their 52-week highs, but they differ significantly in risk and growth. AbbVie shows faster revenue growth and a higher dividend yield, driven by its immunology drugs, but faces...
